SS-31 Dosage & Reconstitution Guide

> Research Use Only Disclaimer: SS-31 (elamipretide) is a research compound intended solely for laboratory and scientific investigation. While elamipretide (Forzinity) received FDA accelerated approval in September 2025 for Barth syndrome, the research-grade peptide discussed in this guide has not been approved for general human therapeutic use beyond that indication. This guide is for informational and educational purposes only. It is not medical advice. Do not self-administer without oversight from a qualified physician or research institution.

---

What Is SS-31 (Elamipretide)?

SS-31 -- also known as elamipretide, Bendavia, and MTP-131 -- is a synthetic, mitochondria-targeted tetrapeptide with the amino acid sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine. This compact four-residue structure was designed by Dr. Hazel Szeto and Dr. Peter Bhatt at Weill Cornell Medical College with one specific goal: reaching and stabilizing the inner mitochondrial membrane (IMM).

What makes SS-31 remarkable is its selectivity. Following subcutaneous administration, it concentrates in the IMM at levels over 1,000-fold higher than in the surrounding cytoplasm. Once there, it binds to cardiolipin -- a phospholipid uniquely found in the IMM that is critical for organizing the electron transport chain (ETC) supercomplexes responsible for ATP synthesis.

In aging, disease, and cellular stress, cardiolipin undergoes oxidation and structural remodeling. This destabilizes ETC supercomplexes, reduces coupling efficiency, increases proton leak, and amplifies mitochondrial reactive oxygen species (ROS) production. SS-31 reverses this cascade: by anchoring to cardiolipin, it stabilizes cristae architecture, restores ETC supercomplex integrity, improves oxidative phosphorylation efficiency, and reduces electron leak that fuels ROS production.

The result, in published preclinical studies, is a broad restoration of mitochondrial bioenergetics -- more ATP produced per unit of oxygen consumed, and less oxidative damage in the process.

Key Facts at a Glance

---

Reconstitution Protocol

Research-grade SS-31 is supplied as a lyophilized (freeze-dried) white powder, typically in 10 mg, 40 mg, or 50 mg vials. Proper reconstitution is essential for dosing accuracy.

Required Materials

• •SS-31 lyophilized vial (e.g., 10 mg)
• •Bacteriostatic water (preferred) or sterile water for injection
• •1 mL or 3 mL syringe with 18-20G draw needle
• •Insulin syringe (U-100, 29-31G) for injection
• •Alcohol swabs

Step-by-Step Reconstitution

1. Prepare your workspace. Wipe the vial septum and bacteriostatic water vial with alcohol swabs. Allow to air dry for 30 seconds.

2. Calculate your diluent volume. The most common concentration for SS-31 is 10 mg/mL, which makes measuring research doses straightforward. For a 10 mg vial: add 1.0 mL of bacteriostatic water.

> Concentration reference: At 10 mg/mL on a U-100 insulin syringe, each 10 IU mark = 0.01 mL = 0.1 mg (100 mcg). A 5 mg dose = 50 IU. A 10 mg dose = 100 IU (full 1 mL syringe).

3. Inject diluent slowly. Point the needle at the inner wall of the vial -- not directly onto the powder. Allow the liquid to run down the glass rather than forcefully mixing.

4. Gently swirl; do not shake. Vortexing or vigorous shaking can denature peptides. Swirl gently in a circular motion until the powder is fully dissolved. The solution should be clear and colorless.

5. Inspect the solution. Discard if you observe cloudiness, particulates, or color. A clear solution is ready for use.

---

Research Dosing Ranges

Clinical Trial Reference Doses

Published clinical trials have used a wide range of SS-31 doses depending on the indication and route of administration:

Intravenous (IV) -- Heart failure Phase 1/2 trials:

• •Ascending-dose study: 0.005, 0.05, and 0.25 mg/kg/hour over a 4-hour infusion
• •The 0.25 mg/kg/h cohort showed significant reductions in left ventricular end-diastolic and end-systolic volumes

Subcutaneous (SC) -- PROGRESS-HF Phase 2 (heart failure):

• •4 mg/day SC x 28 days
• •40 mg/day SC x 28 days
• •Both doses demonstrated a favorable tolerability profile

Subcutaneous (SC) -- TAZPOWER (Barth syndrome):

• •40 mg/day SC, studied for up to 168 weeks in the open-label extension
• •This dose and formulation became the basis for FDA-approved Forzinity

Subcutaneous (SC) -- Primary Mitochondrial Myopathy (MMPOWER-3):

• •40 mg/day SC, Phase 3 trial

Research Protocol Dosing (2-10 mg Range)

In investigational contexts outside of established clinical trials, SS-31 is commonly explored in lower dose ranges. Published preclinical animal studies, pharmacokinetic modeling, and physician-supervised longevity medicine contexts have explored a range of 2-10 mg per day subcutaneously for general mitochondrial research objectives.

> Note on 1-3 mg/day range: The issue brief notes a published 1-3 mg/day range seen in some studies. These figures appear in certain dose-ranging investigations and pharmacokinetic modeling, but the majority of Phase 2 and Phase 3 human trials began SC testing at 4 mg/day as their lower bound. Researchers should reference primary literature for the exact indication and model they are studying.

---

Subcutaneous Injection Protocol

Injection Site Selection

For SS-31 subcutaneous administration, preferred sites are:

• •Abdomen -- 2 inches from the navel, alternating left and right sides
• •Outer thigh -- mid-thigh, rotating between legs
• •Upper arm (lateral aspect) -- less common; requires assistance for self-injection

Rotate injection sites daily. Prolonged daily injection at the same site can cause localized tissue reactions, including redness, induration, and lipohypertrophy.

Injection Technique

1. Clean the injection site with an alcohol swab; allow to dry.

2. Pinch a fold of skin between thumb and index finger.

3. Insert the insulin needle at a 45-90 degree angle depending on subcutaneous tissue depth.

4. Inject slowly over 5-10 seconds to minimize discomfort.

5. Withdraw the needle; apply gentle pressure with a clean swab. Do not rub.

6. Dispose of the needle safely in a sharps container.

For doses above 1 mL, clinical pharmacology protocols recommend splitting the dose across two injection sites to reduce local volume load.

Injection Site Reactions

The most consistently reported adverse event across SS-31 clinical trials is mild injection site reactions -- transient redness, warmth, or minor itching. These reactions were considered mild and did not require discontinuation in published trials lasting up to 24 weeks. Site rotation is the primary mitigation strategy.

---

Timing and Exercise Considerations

Pharmacokinetic Basis for Timing

SS-31 has a plasma half-life of approximately 4 hours following subcutaneous administration. Peak plasma concentrations occur within 60-90 minutes of injection. By hour 6-8, plasma levels have declined substantially. This half-life creates an important consideration for dosing strategy:

• •Once-daily dosing creates a window of peak mitochondrial membrane support lasting approximately 4-6 hours, with declining coverage for the remainder of the day.
• •Twice-daily (BID) dosing -- splitting the total daily dose into two injections spaced 8-12 hours apart -- has been explored in some research contexts to maintain more sustained mitochondrial membrane engagement. However, clinical trials have primarily used once-daily protocols.

Timing Relative to Exercise

For researchers investigating SS-31's interaction with exercise-induced mitochondrial stress, timing the injection 30-60 minutes before exercise is a logical protocol design choice. This positions peak plasma and mitochondrial membrane concentrations during the period of highest energetic demand and oxidative stress.

In aged mouse studies, SS-31 reversed age-related cardiac diastolic dysfunction and restored skeletal muscle energetic deficits, with researchers noting normalization of proton leak and ROS production in muscle tissue. Human exercise physiology studies with SS-31 remain limited, but the mechanistic rationale for pre-exercise timing is coherent.

Alternatively, morning administration is the most common approach in clinical trials, offering practical consistency without requiring coordination with training schedules.

Cardiac Research Contexts

SS-31 has been extensively studied in cardiac ischemia-reperfusion injury models, where the mechanism of injury involves acute mitochondrial dysfunction, cardiolipin peroxidation, and ETC supercomplex destabilization. In these preclinical models, SS-31 administered before ischemic insult or during early reperfusion significantly reduced infarct size, improved mitochondrial function, and restored cardiac function.

For heart failure research contexts, both the Phase 1/2 IV trial and the PROGRESS-HF SC trial used fixed-time daily administration rather than exercise-coordinated protocols.

---

Cycling Considerations

Clinical trials have evaluated elamipretide in continuous daily administration for up to 168 weeks in the TAZPOWER open-label extension study for Barth syndrome, with no evidence of tolerance development, diminishing efficacy, or cumulative safety signals.

For research contexts not bound by clinical trial protocols, some investigators implement cycle structures such as 8-12 weeks on, followed by 4 weeks off -- though this approach is not supported by clinical trial evidence showing a need for cycling. The rationale often cited is precautionary rather than evidence-based.

---

Storage and Stability

Proper storage is essential for SS-31 potency. The peptide is sensitive to heat, oxidation, and repeated freeze-thaw cycling.

Lyophilized (Unreconstituted) Powder

SS-31 must be kept frozen in its lyophilized state for maximum stability. Unlike some peptides that tolerate refrigeration, the lyophilized powder should be stored at -20 degrees C until the day of reconstitution.

Reconstituted Solution

Once reconstituted with bacteriostatic water, the solution should be refrigerated (not frozen) and used within 4 weeks. Use sterile technique on every draw to prevent microbial contamination.

> Freeze-thaw cycles: Each freeze-thaw cycle increases the risk of peptide aggregation and activity loss. Draw only what you need per session; avoid repeatedly freezing and thawing the same vial.

---

Comparison to Other Mitochondrial Peptides: Dosing Approach

SS-31, MOTS-c, and Humanin are three of the most studied mitochondrial peptides. While all three target mitochondrial health, their mechanisms, origins, and dosing approaches differ substantially.

For a detailed mechanistic comparison, see our full article: Mitochondrial-Derived Peptides Compared: Humanin vs MOTS-c vs SS-31.

Mechanism Differences Drive Dosing Philosophy

Why MOTS-c Uses Intermittent Dosing While SS-31 Is Daily

MOTS-c functions primarily as a signaling peptide -- it activates AMPK, regulates metabolic gene expression, and mimics aspects of exercise signaling. Its effects are downstream of the signal pulse rather than requiring continuous presence. This is analogous to a software instruction: you send the command, the cell executes the program. Intermittent pulses (2-3x/week) are therefore sufficient and may actually better mimic the natural exercise-induced secretion pattern.

SS-31, by contrast, performs a structural function at the inner mitochondrial membrane. It physically stabilizes cardiolipin and ETC supercomplexes while it is present. When plasma levels drop (after ~6-8 hours), the structural support diminishes. This is why once-daily or twice-daily continuous dosing is used in clinical trials -- the benefit requires ongoing presence.

Humanin's mechanism overlaps more with MOTS-c's signaling role (anti-apoptotic, cytoprotective pathways), which similarly supports intermittent protocols.

Stacking Context

Because SS-31 (structural membrane stabilization) and MOTS-c (AMPK metabolic signaling) act through completely non-overlapping mechanisms, they are often considered complementary in research stacks. No published studies have formally evaluated this combination, but their mechanistic independence suggests no pharmacological conflict. CoQ10 and NAD+ precursors are also frequently paired in research protocols targeting comprehensive mitochondrial bioenergetics.

---

Key Published Studies

Researchers designing SS-31 protocols should consult primary literature. Key reference studies include:

Heart failure (IV): Sabbah et al. (2020), JACC: Basic to Translational Science -- Phase 1/2 dose-escalation study demonstrating significant LV volume reduction at 0.25 mg/kg/h IV in HFrEF patients.

Heart failure (SC): Daubert et al. (2020), JACC: Heart Failure -- PROGRESS-HF Phase 2 RCT evaluating 4 mg and 40 mg SC daily x 28 days in HFrEF; well-tolerated across both doses.

Barth syndrome (SC long-term): Thompson et al. (2024), Genetics in Medicine -- TAZPOWER open-label extension through 168 weeks; favorable long-term safety and tolerability at 40 mg/day.

AMD (SC): ReCLAIM-2 Phase 2 trial, Ophthalmology Retina (2024) -- evaluating elamipretide in non-central geographic atrophy.

Aging/skeletal muscle (preclinical): Siegel et al. -- Aged mouse model showing SS-31 reversed energetic deficits, improved resting and dynamic muscle function, and restored redox homeostasis in skeletal muscle.

Cardiac aging (preclinical): Dai et al. -- Eight weeks of SS-31 at 3 mg/kg/day in aged mice substantially reversed cardiac diastolic dysfunction and normalized mitochondrial ROS production.

---

Research Context and Limitations

Several important caveats apply to any research use of SS-31:

No general human-use approval: Despite the September 2025 FDA accelerated approval for Barth syndrome, research-grade SS-31 is not FDA-approved for other indications. Barth syndrome is a rare, genetically confirmed mitochondrial disorder -- the approval does not extend to healthy adults, longevity applications, or general mitochondrial support.

Human longevity data is limited: The mechanistic case for SS-31 in aging is strong and well-supported by preclinical data. Human RCT data in healthy adults does not yet exist. Results from disease populations (heart failure, Barth syndrome) cannot be directly extrapolated.

Dose-response in healthy adults is unknown: The right dose for a research investigation in a healthy 40-year-old may be entirely different from the 40 mg/day dose studied in a 65-year-old with systolic heart failure or a child with Barth syndrome.

Injection site reactions are the most common AE: Across all clinical trials, injection site redness and irritation are the most consistently reported side effects. Monitoring and rotation minimize risk.

Renal function monitoring: Clinical protocols recommend monitoring renal function (eGFR, creatinine) at baseline and periodically. Dose adjustment considerations apply at eGFR <30.

---

Further Reading

• •SS-31 (Elamipretide): Mitochondria-Targeted Tetrapeptide -- Full Research Profile
• •Mitochondrial-Derived Peptides Compared: Humanin vs MOTS-c vs SS-31

---

This article is for educational and research purposes only. It does not constitute medical advice. SS-31 (research grade) is intended for laboratory research use. Always consult a licensed healthcare professional or principal investigator before designing or implementing any peptide research protocol.